The final 5-year analysis of the CheckMate 025 trial comprising patients with advanced renal cell carcinoma confirms the enhanced survival benefits of nivolumab versus everolimus.
Durability and survival results from the phase 1b EV-103 trial provide further support for the combination of enfortumab vedotin and pembrolizumab as a promising first-line option for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma.
The combination of cabozantinib and atezolizumab has antitumor activity and a manageable safety profile in men with metastatic castration-resistant prostate cancer, indicate preliminary trial data.
Results of the phase 2 ATLAS trial do not support use of the PARP inhibitor rucaparib in patients with recurrent, locally advanced, or metastatic urothelial carcinoma, the investigators have reported.
Findings from two phase 2 trials suggest that combining immune checkpoint inhibition with stereotactic body radiotherapy is feasible in patients with metastatic renal cell carcinoma.
This independent news story was supported by an educational grant from Pfizer and Merck KGaA
SEMITEP trial results reported at the 2020 Genitourinary Cancers Symposium demonstrate the feasibility of treatment de-escalation based on an interim scan in metastatic seminoma patients with good prognosis.
The adenovirus vector-based gene therapy nadofaragene firadenovec elicits durable responses in people with non-muscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin, shows a phase 3 trial.
The patient-reported outcomes from the CARD trial of third-line cabazitaxel in men with metastatic castration-resistant prostate cancer add support for using the taxane in this setting, say researchers.
The 8-year results from the phase 3 CHHiP trial have confirmed the noninferiority of moderately hypofractionated radiotherapy delivering 60 Gy in 20 fractions to the conventional regimen for the control of localized prostate cancer.
Metastasis-directed therapy for oligometastatic recurrent prostate cancer continues to be associated with better androgen deprivation therapy-free survival relative to surveillance at 5 years, show follow-up findings from the STOMP trial.
US researchers highlight the need for follow-up of stage IV non-small-cell lung cancer patients who receive first-line EGFR–tyrosine kinase inhibitor therapy, finding few patients subsequently undergo testing for the T790M mutation.
Lurbinectedin has clinical activity and acceptable toxicity in the second- and third-line treatment of malignant pleural mesothelioma, say phase 2 trial investigators.
Combining a single nucleotide polymorphism-based genetic risk score for prostate cancer with family history could improve the stratification of inherited risk and help personalize screening strategies, research suggests.
US researchers report a decrease in the use of key indicators of comprehensive diabetes care in the year following a cancer diagnosis among people with diabetes.
Use of a patient decision aid video improves informed decision-making about lung cancer screening among people accessing smoking cessation services in the USA, study findings indicate.
Individuals receiving atezolizumab for advanced non-small-cell lung cancer may have worse survival if they are also taking antibiotics or proton pump inhibitors, indicates an analysis of the POPLAR and OAK trials.
Real-world data show comparable patient reported functional outcomes and health-related quality of life between nonmetastatic prostate cancer patients who were treated with moderately hypofractionated or conventionally fractionated radiation therapy.
Individuals at high risk for developing lung cancer benefit from periodic screening with low-dose computed tomography, indicate the 10-year results from the NELSON trial.